ImmunoPrecise Antibodies Ltd. Files 6-K Report
Ticker: HYFT · Form: 6-K · Filed: Dec 3, 2024 · CIK: 1715925
Sentiment: neutral
Topics: filing, press-release
TL;DR
IPA files 6-K with press release on Dec 3rd - check for updates.
AI Summary
ImmunoPrecise Antibodies Ltd. filed a Form 6-K on December 3, 2024, to report a press release dated December 3, 2024. The filing does not contain specific financial figures or operational details beyond the announcement of the press release.
Why It Matters
This filing indicates that ImmunoPrecise Antibodies Ltd. has made a public announcement, likely containing important business updates or financial information, which is now available for investors to review.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves to attach a press release, with no new material financial or operational information disclosed within the filing itself.
Key Players & Entities
- ImmunoPrecise Antibodies Ltd. (company) — Registrant
- Kristin Taylor (person) — Signatory for the company
- December 3, 2024 (date) — Date of press release and filing
FAQ
What is the primary purpose of this 6-K filing?
The primary purpose of this 6-K filing is to report a press release dated December 3, 2024, as required for foreign private issuers.
What is the Commission File Number for ImmunoPrecise Antibodies Ltd.?
The Commission File Number for ImmunoPrecise Antibodies Ltd. is 001-39530.
What type of annual report does ImmunoPrecise Antibodies Ltd. file?
ImmunoPrecise Antibodies Ltd. files its annual reports under cover of Form 20-F.
Where is ImmunoPrecise Antibodies Ltd. located?
ImmunoPrecise Antibodies Ltd. is located at 3204 - 4464 Markham Street, Victoria, British Columbia V8Z 7X8.
What exhibit is included with this 6-K filing?
Exhibit 99.1, a Press Release dated December 3, 2024, is included with this 6-K filing.
Filing Stats: 143 words · 1 min read · ~1 pages · Grade level 11.2 · Accepted 2024-12-03 08:33:42
Filing Documents
- earnings_release_date_de.htm (6-K) — 22KB
- ipa-ex99_1.htm (EX-99.1) — 14KB
- 0000950170-24-132464.txt ( ) — 37KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. IMMUNOPRECISE ANTIBODIES LTD. Date: December 3, 2024 By: /s/ Kristin Taylor Name: Kristin Taylor Title: Chief Financial Officer